Medical Department, Mondial Assistance France, Paris, France.
J Travel Med. 2013 Jan-Feb;20(1):22-8. doi: 10.1111/j.1708-8305.2012.00668.x. Epub 2012 Nov 22.
The repatriation of patients from foreign hospitals can foster the emergence and spread of multidrug-resistant bacteria (MRB). We aimed to evaluate the incidence of MRB in patients treated in foreign hospitals and repatriated by international inter-hospital air transport in order to better manage these patients and adjust our procedures.
The records from all consecutive aeromedical evacuations and overseas repatriations carried out by Mondial Assistance France between December 2010 and November 2011 were reviewed for this study. Only inter-hospital transfers with inpatient destination of an acute care unit were considered. Patients were allocated to one of two groups: those identified as MRB carriers at their arrival in France and those who were not identified as such (either negative for MRB or not tested). Data were compared between the two groups.
Analysis was performed on 223 patients: 16 patients (7%) were identified as MRB carriers. Compared with confirmed non-MRB patients, MRB carriers came more frequently from a high-risk unit (88% vs 59%, p = 0.05) and had a longer foreign hospital stay [13 (3-20) vs 8 (6-14) d, p = 0.01].
The occurrence of MRB among patients repatriated from foreign hospitals is noted in a significant minority of such individuals transferred back to their home country. The typical MRB patient was admitted to a high-risk unit in a foreign hospital prior to repatriation with longer foreign hospital admissions. The prospective identification of these patients prior to transport is difficult. While these factors are associated with MRB presence, their absence does not rule out highly resistant bacterial colonization. A systematic review of this important medical issue is warranted with the development of guidelines.
从国外医院遣返的患者可能会导致耐多药细菌(MRB)的出现和传播。我们旨在评估在国外医院接受治疗并通过国际医院间空运遣返的患者中 MRB 的发生率,以便更好地管理这些患者并调整我们的程序。
本研究回顾了 2010 年 12 月至 2011 年 11 月期间法国 Mondial Assistance 进行的所有连续航空医疗后送和海外遣返的记录。仅考虑住院目的地为急症病房的医院间转院。患者被分为两组:一组是在抵达法国时被确认为 MRB 携带者的患者,另一组是未被确认为 MRB 携带者的患者(MRB 阴性或未检测)。比较两组患者的数据。
分析了 223 名患者:16 名患者(7%)被确认为 MRB 携带者。与确认为非 MRB 患者相比,MRB 携带者更多地来自高危病房(88%比 59%,p=0.05),且在国外的住院时间更长[13(3-20)比 8(6-14)天,p=0.01]。
从国外医院遣返的患者中,MRB 的发生率在返回原籍国的患者中占少数。典型的 MRB 患者在被遣返前曾在国外的高危病房住院,且在国外的住院时间较长。在运输前对这些患者进行前瞻性识别较为困难。尽管这些因素与 MRB 的存在相关,但它们的缺失并不能排除高度耐药细菌定植的情况。需要对此重要的医学问题进行系统评价,并制定相应的指南。